In a Phase IIa clinical trial for the treatment of Idiopathic Pulmonary Fibrosis (IPF), Insilico Medicine's TNIK inhibitor Rentosertib (ISM001-055), developed leveraging its advanced AI platform, demonstrated favorable safety and tolerability profiles. Notably, dose-dependent improvements in lung function were observed. These groundbreaking results have been published in Nature Medicine, marking the industry's first successful clinical proof-of-concept for an AI-driven drug discovery project. Furthermore, exploratory biomarker analyses provided additional validation of the TNIK target's biological mechanism, solidifying the foundation for subsequent, larger-scale clinical trials. Insilico Medicine highlighted that its AI technology drastically enhanced drug discovery efficiency, reducing the average time from project inception to the identification of a preclinical candidate molecule to just 12-18 months.